Recent advancements in CAR T-cell therapies targeting B cells, especially those directed at CD19 and BCMA, have demonstrated significant promise in managing autoimmune conditions such as SLE, MS, and PV [1,[20], [21], [22],[26], [27], [28], [29]]. This evidence concerns the gene TNFRSF17 and myeloid sarcoma.